公开(公告)号：US20100135966A1

公开(公告)日：2010-06-03

申请号：US12624271

申请日：2009-11-23

申请人： Ulrich Schubert ,  Hans Will ,  Hüseyin Sirma

发明人： Ulrich Schubert ,  Hans Will ,  Hüseyin Sirma

IPC分类号： A61K35/12 ,  A61K31/40 ,  A61K31/336

CPC分类号： A61K31/69 ,  A61K31/11 ,  A61K31/16 ,  A61K38/06

摘要： The invention relates to agents for the treatment, therapy and inhibition of Flaviviridae virus infections, which agents comprise proteasome inhibitors as the active component. The agents which are used for inhibiting the release, maturation and replication of Flaviviridae comprise, as the active component in pharmaceutical preparations, substance classes which share the common property of inhibiting the 26S proteasome in cells. These substance classes include, in particular, proteasome inhibitors which affect the activities of the ubiquitin/proteasome pathway, in particular the enzymic activities of the 26S and the 20S proteasome complex. The application of the invention lies in the antiviral therapy of Flaviviridae infections, especially in preventing the establishment and maintenance of a chronic hepatitis C virus infection and a hepatopathogenesis which is associated therewith.

摘要翻译： 本发明涉及用于治疗，治疗和抑制黄病毒科病毒感染的药剂，该药物包含作为活性成分的蛋白酶体抑制剂。 用于抑制黄病毒科的释放，成熟和复制的药物包含作为药物制剂中的活性成分的具有抑制细胞中26S蛋白酶体的共同性质的物质类别。 这些物质类别特别包括影响泛素/蛋白酶体途径的活性的蛋白酶体抑制剂，特别是26S和20S蛋白酶体复合物的酶活性。 本发明的应用在于黄病毒科感染的抗病毒治疗，特别是在预防慢性丙型肝炎病毒感染的建立和维持以及与之相关的肝癌发病。